Promising skin cancer combo trial halted early
NCT ID NCT04913220
First seen Feb 04, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tested a new drug (SAR444245) combined with an immunotherapy (cemiplimab) for people with advanced melanoma or squamous cell skin cancer that could not be removed by surgery. The goal was to see if the combination could shrink tumors. The trial was stopped early, and results are limited. It involved 46 adults with advanced skin cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beverly Hills Cancer Center & Optima Diagnostic Imaging Site Number : 8400007
Beverly Hills, California, 90211, United States
-
Investigational Site Number : 0360001
Macquarie University, New South Wales, 2109, Australia
-
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, 8420383, Chile
-
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, 7500921, Chile
-
Investigational Site Number : 1520003
Temuco, 4800827, Chile
-
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
-
Investigational Site Number : 1520005
Santaigo, Reg Metropolitana de Santiago, 8241470, Chile
-
Investigational Site Number : 1520006
Antofagasta, 1420000, Chile
-
Investigational Site Number : 2500001
Nantes, 44093, France
-
Investigational Site Number : 2500002
Dijon, 21079, France
-
Investigational Site Number : 2500003
Bobigny, 93009, France
-
Investigational Site Number : 2500005
Lille, 59037, France
-
Investigational Site Number : 2500006
Pierre-Bénite, 69495, France
-
Investigational Site Number : 2760001
Hamburg, 20246, Germany
-
Investigational Site Number : 2760003
Mannheim, 68167, Germany
-
Investigational Site Number : 2760004
Berlin, 10117, Germany
-
Investigational Site Number : 2760005
München, 80337, Germany
-
Investigational Site Number : 2760006
Minden, 32429, Germany
-
Investigational Site Number : 3800001
Naples, 80131, Italy
-
Investigational Site Number : 3800004
Perugia, 06126, Italy
-
Investigational Site Number : 7240001
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240002
Santander, Cantabria, 39008, Spain
-
Investigational Site Number : 7240003
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
-
Investigational Site Number : 7240004
Barcelona, Barcelona [Barcelona], 08036, Spain
Conditions
Explore the condition pages connected to this study.